Senseonics Holdings Inc
AMEX:SENS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (12.9), the stock would be worth $-26.03 (465% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -3.5 | $7.13 |
0%
|
| Industry Average | 12.9 | $-26.03 |
-465%
|
| Country Average | 14.4 | $-28.99 |
-507%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
S
|
Senseonics Holdings Inc
AMEX:SENS
|
288.9m USD | -3.5 | -4.3 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
170B USD | 45.1 | 59.4 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
160.6B USD | 13.8 | 25.3 | |
| US |
|
Stryker Corp
NYSE:SYK
|
126.1B USD | 19.7 | 38.5 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
107.5B USD | 12.9 | 23.1 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
97.4B USD | 19 | 32.1 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40.6B EUR | 10.7 | 18.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
46.3B USD | 24.7 | 45.2 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.7B USD | 29.8 | 42.1 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
44.1B USD | 9.9 | 24.9 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32B USD | 15 | 21.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Senseonics Holdings Inc
Glance View
Senseonics Holdings, Inc. engages in the design, development, and commercialization of an implantable continuous glucose monitoring system for people with diabetes. The company is headquartered in Germantown, Maryland and currently employs 121 full-time employees. The company went IPO on 2015-03-04. The firm is focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community. Its Eversense, Eversense XL, and Eversense E3 continuous glucose monitoring (CGM) systems are designed to continually measure glucose levels in people with diabetes via an under-the-skin sensor, a removable and rechargeable smart transmitter, and a mobile application for real-time diabetes monitoring and management for a period of up to six months. The company is also developing its Gemini product variation to allow for a two-in-one glucose monitoring system combining the functionality of CGM and Flash Glucose Monitoring (FGM), in an implantable sensor that may be utilized with a smart transmitter to get continuous glucose readings and alerts or be utilized through a swipe over the sensor with a smart phone to get on-demand glucose readings without a smart transmitter.
